Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment.

Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment. Abstract Text:

The presence of left ventricular hypertrophy (LVH) in hypertensive patients, recognized clinically by electrocardiography or echocardiography, is an adverse prognostic sign and a powerful predictor of cardiovascular morbidity and mortality, independent of blood pressure and other cardiovascular risk factors. Several pathophysiological changes accompany the myocytic growth and fibrosis that characterize hypertensive LVH and have been invoked to explain the association of LVH with increased cardiovascular risk. These include: impairment of diastolic function, and probably also of systolic performance, at least during exercise; reduced coronary blood flow reserve; predisposition to ventricular arrhythmias; alteration in cardiac autonomic nervous system activity. All these data have led to the opinion that regression of LVH should be a major goal in the treatment of hypertensive patients and might predict an improvement in prognosis.

Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment. Publishing Authors By Initials

For similar diagnosis: prognosis research abstracts see: diagnosis: prognosis research

PUBMED ID PMID:

MEDLINE DATE:

Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment. Journal Published:

PUBLICATION TYPE: Review

Journal: Blood pressure. Supplement

VOLUME: 2

Page Numbers: 13-5

Journal Abbreviation:

ISSN: 0803-8023

DAY: 26

MONTH: 02

YEAR: 1997

Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment. Information

Number of References: 12

LANGUAGE: eng

NlmUniqueID: 9300787

Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment. Keywords Mesh Terms:

KEYWORDS: Prognosis

MESH TERMS: therapy

Chemical & Substance for Abstract: Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment. Information

Substance Name: Antihypertensive Agents

Registry Number: 0

Grant and Affiliation Information for Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment.

AFFILIATION: Semiotica and Metodologia Medica, University of Brescia, Italy. agabiti@master.cci.unibs.it

Country: NORWAY

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Blood Press Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment Related Publications

• Antidiuretic hormone and atrial natriuretic peptide during lower body negative or positive pressure in hypertensive patients with and without left ventricular hypertrophy.
• Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment.
• Inappropriate left ventricular mass in patients with primary aldosteronism.
• Macro and microvasculature in hypertension: therapeutic aspects.
• Myocardial ultrasound tissue characterization in patients with chronic renal failure.
• Nitric oxide in the regulation of vascular systemic resistance.
• Prognostic role of flow-mediated dilatation of the brachial artery in hypertensive patients.